Regenerative Biologics Supplier for Orthopedic Practices in Orlando, FL

Vendor qualification for orthopedic groups

Orthopedic practices and ambulatory surgery centers generally run new biologics suppliers through a standard vendor qualification process before any purchase order is issued. That process typically covers corporate registration, product documentation, insurance or liability review, and confirmation that ordering will be restricted to licensed clinicians on staff.

Precision Biologics supports this process by making certificate of analysis, donor eligibility summary, and lot release record documentation available on request, along with a point of contact for questions about account setup and recordkeeping.

NPI-verified accounts

Every Precision Biologics account is tied to a National Provider Identifier. During setup, a practice provides its NPI along with basic practice information, which is checked against the NPPES registry before the account is approved for ordering.

This verification step is separate from any clinical decision about a product; it confirms only that the purchasing account belongs to a licensed professional or practice entity.

Receiving and cold-chain logistics

Cryopreserved products ship overnight on dry ice in validated containers and are stored at -80 degrees C prior to shipment. Practices receiving shipments in the Southeast should confirm a staff member is available to receive and log the delivery on the day it is scheduled to arrive, since cold-chain product requires prompt transfer to proper storage.

Each shipment carries a unique lot identifier so the receiving practice can record lot information at the patient record level for traceability.

Confirming regulatory posture before ordering

Whether a particular intended use of a Wharton's jelly product fits within the section 361 framework described in 21 CFR 1271.10 is a determination each practice makes with its own counsel, not something Precision Biologics assesses on a clinic's behalf.

Florida enacted SB 1768, effective July 1, 2025, addressing physician use of certain non-FDA-approved stem cell therapies in orthopedics, wound care, and pain management under informed consent and disclosure requirements; it does not change federal FDA requirements that apply to the product itself. Practices should verify current applicability with the Florida Board of Medicine and their own counsel before making purchasing or use decisions.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.